Davis Polk advises AstraZeneca on $15b spin-off and merger

Author: | Published: 1 Jan 2000

Davis Polk & Wardwell, Freshfields and Homburger Rechtanswalte are advising AstraZeneca on the spin-off of its agricultural chemical business, which will be simultaneously merged with an equivalent spin-off from Swiss pharmaceuticals company Novartis. The merged company, to be...